Proving the value of boundary-pushing medical products

Demonstrating safety and efficacy may be job one for life science companies working to bring new drugs and diagnostics to market, but they are hardly the whole game anymore.

As recent events in the Alzheimer’s space indicate, anticipating the needs and expectations of regulators and HTA bodies is increasingly critical to commercializing new healthcare products. As innovators push beyond established modalities and well-understood conditions, pharmas, biotechs and medtechs are being challenged to engage regulators earlier and in greater depth in order to smooth their products’ path to market.

In this panel, Clarivate’s market access and therapy area experts will discuss how companies can navigate the emerging regulatory landscape and shorten time to market for needed diagnostics and treatments.

  • Date:
    June 7, 2022
  • Start Time:
    10:30 am EDT
  • End Time:
    11:30 am EDT
  • Share: